Closed-loop delivery of insulin: Progress to date for diabetes mellitus therapy

American Journal of Drug Delivery

Volumn 2, Issue 1, 2004, Pages 1-13

  Taylor, M Joan ^a   Tanna, Sangeeta ^a   Sahota, Tarsem S ^a  

^a DE MONTFORT UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; CAPTOPRIL; DACLIZUMAB; GLUCORECEPTOR; GLUCOSE; IMMUNOSUPPRESSIVE AGENT; INSULIN; RAPAMYCIN; TACROLIMUS; TRANSCRIPTION FACTOR PDX 1;

CELL DIFFERENTIATION; CELL LOSS; CELL POPULATION; CONTINUOUS INFUSION; DIABETES MELLITUS; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG RELEASE; GENE THERAPY; GLUCOSE BLOOD LEVEL; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HYPERTENSION; HYPOGLYCEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFUSION PUMP; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INSULIN PUMP; MINIPUMP; MOUSE; MULTIPLE DRUG DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS TRANSPLANTATION; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; RISK BENEFIT ANALYSIS; SENSOR; VIRAL GENE DELIVERY SYSTEM;

EID: 2942541584     PISSN: 11759038     EISSN: None     Source Type: Journal    
DOI: 10.2165/00137696-200402010-00001     Document Type: Review

References (158)

1. Lifetime benefits and costs of intensive therapy as practiced in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group. JAMA 1996; 276: 1409-15
2. DeFronzo RA. Implications of the United Kingdom Prospective Diabetes Study. Prim Care 1999; 26: 809-27
3. Orchard T, Forrest K, Ellis D, et al. Cumulative glycemic exposure and microvascular complications in insulin-dependent diabetes mellitus: the glycemic threshold revisited. Arch Intern Med 1997; 157: 1851-6
4. Trehan A, Ali A. Recent approaches in insulin delivery. Drug Dev Ind Pharm 1998; 24: 589-97
5. Renard E, Costalat G, Bringer J. From external to implantable insulin pump, can we close the loop? Diabetes Metab 2002; 28: 2S19-25
6. Daneman D. Islet cell transplantation and other new technologies for treating type 1 diabetes: a paediatric view. Horm Res 2002; 57 Suppl 1: 54-9.
7. Miyamoto M. Current progress and perspectives in cell therapy for diabetes mellitus. Hum Cell 2001; 14: 293-300
8. Petrovsky N, Silva D, Schatz DA. Prospects for the prevention and reversal of type 1 diabetes mellitus. Drugs 2002; 62: 2617-35
9. Williams G, Pickup JC. Handbook of diabetes. Oxford: Blackwell Science, 1999
10. Kelly WD, Lillehei RC, Merkel FK, et al. Allotransplantation of the pancreas and duodenum along with the kidney in diabetic neuropathy. Surgery 1967; 61: 827-37
11. Bilous R, Mauer SM, Sutherland DE, et al. The effects of pancreas transplantation on the glomerular structure of renal-allografts in patients with insulin-dependent diabetes. N Engl J Med 1989; 321: 80-5
12. Paty BW, Lanz K, Kendall DM, et al. Restored hypoglycemic counterregulation is stable in successful pancreas transplant recipients for up to 19 years after transplantation. Transplantation 2001; 72: 1103-7
13. Al-Shurafa HA, Jawdat MT, Bassas AF, et al. Innovations in pancreas transplantation. Saudi Med J 2002; 23: 265-71
14. Larsen J, Lane J, Mack-Shipman L. Pancreas and kidney transplantation. Curr Diab Rep 2002; 2: 359-64
15. Pileggi A, Ricordi C, Alessiani M, et al. Factors influencing Islet of Langerhans graft function and monitoring. Clin Chim Acta 2001; 310: 3-16
16. Ryan EA, Lakey JR, Rajotte RV, et al. Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol. Diabetes 2001; 50: 710-9
17. Humar A, Khwaja K, Ramcharan T, et al. Chronic rejection: the next major challenge for pancreas transplant recipients. Transplantation 2003; 76: 918-23
18. Bakr MA, Refaie A, Ihab MH, et al. Experimental islet cell transplantation in rats. Transplant Proc 1997; 29: 2908-11
19. Calafiore R, Luca G, Calvitti M, et al. Cellular support systems for alginate microcapsules containing islets, as composite bioartificial pancreas. Ann NY Acad Sci 2001; 944: 240-51
20. Burridge PW, Shapiro AM, Ryan EA, et al. Future trends in clinical islet transplantation. Transplant Proc 2002; 34: 3347-8
21. Robertson RP, Lanz KJ, Sutherland DE, et al. Prevention of diabetes for up to 13 years by autoislet transplantation after pancreatectomy for chronic pancreatitis. Diabetes 2001; 50: 47-50
22. Robertson RP. Islet transplantation: travels up the learning curve. Curr Diab Rep 2002; 2: 365-70
23. Gill I, Ballesteros A. Bioencapsulation within synthetic polymers (Pt 1): sol-gel encapsulated biologicals. Trends Biotechnol 2000; 18: 282-96
24. Soon-Shiong P. Treatment of type 1 diabetes using encapsulated islets. Adv Drug Deliv Rev 1993; 35: 259-70
25. Soon-Shiong P, Feldman E, Nelson R, et al. Long-term reversal of diabetes by the injection of immunoprotected islets. Proc Natl Acad Sci USA 1993; 90: 5843-7
26. Mullen Y, Maruyama M, Smith CV. Current progress and perspectives in immunoisolated islet transplantation. J Hepatobiliary Pancreat Surg 2000; 7: 347-57
27. Pope EJA, Braun K, Peterson C. Bioartificial organs (I). Silica gel encapsulated pancreatic islets for the treatment of diabetes mellitus. J Sol Gel Sci Technol 1997; 8: 635-9
28. Tao SL, Desai TA. Microfabricated drug delivery systems: from particles to pores. Adv Drug Deliv Rev 2003; 55: 315-28
29. Contreras JL, Bilbao G, Smyth CA, et al. Cytoprotection of pancreatic islets before and early after transplantation using gene therapy. Kidney Int Suppl 2002; 61 Suppl. 1: 79-84
30. Bonner-Weir S, Sharma A. Pancreatic stem cells. J Pathol 2002; 197: 519-26
31. Efrat S. Cell replacement therapy for type 1 diabetes. Trends Mol Med 2002; 8: 334-40
32. Efrat S. Preventing type 1 diabetes mellitus: the promise of gene therapy. Am J Pharmacogenomics 2002; 2: 129-34
33. Gu YJ, Cui WX, Miyamoto M, et al. Development of a new bioartificial pancreas possessing angiogenesis-inducing function [abstract]. Transplant Proc 2000; 32: 2475
34. Thivolet C. New therapeutic approaches to type 1 diabetes: from prevention to cellular or gene therapies. Clin Endocrinol (Oxf) 2001; 55: 565-74
35. Mahato RI, Henry J, Narang AS, et al. Cationic lipid and polymer-based gene delivery to human pancreatic islets. Mol Ther 2003; 7: 89-100
36. Fleischer N, Chen C, Surana M, et al. Functional analysis of a conditionally transformed pancreatic beta-cell line. Diabetes 1998; 47: 1419-25
37. Taniguchi H, Yamato E, Tashiro F, et al. Beta-cell neogenesis induced by adenovirus-mediated gene delivery of transcription factor pdx-1 into mouse pancreas. Gene Ther 2003; 10: 15-23
38. Xu R, Li H, Tse LY, et al. Diabetes gene therapy: potential and challenges. Curr Gene Ther 2003; 3: 65-82
39. Gros L, Riu E, Montoliu L, et al. Insulin production by engineered muscle cells. Hum Gene Ther 1999; 10: 1207-17
40. Riu E, Mas A, Ferre T, et al. Counteraction of type 1 diabetic alterations by engineering skeletal muscle to produce insulin: insights from transgenic mice. Diabetes 2002; 51: 704-11
41. Falqui L, Martinenghi S, Severini GM, et al. Reversal of diabetes in mice by implantation of human fibroblasts genetically engineered to release mature human insulin. Hum Gene Ther 1999; 10: 1753-62
42. Thulé PM, Liu JM. Regulated hepatic insulin gene therapy of STZ-diabetic rats. Gene Ther 2000; 7: 1744-52
43. Sasaki S, Nio Y, Hirahara N, et al. Intraperitoneally implanted artificial pancreas with transkaryotic beta-cells on microcarrier beads in a diffusion chamber improves hyperglycemia after 90% pancreatectomy in rats. In Vivo 2000; 14: 535-41
44. Wang W, Gu Y, Tabata Y, et al. Reversal of diabetes in mice by xenotransplantation of a bioartificial pancreas in a prevascularized subcutaneous site. Transplantation 2002; 73: 122-9
45. Stoffers DA, Kieffer TJ, Hussain MA, et al. Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 2000; 49: 741-8
46. Thulé PM, Liu J, Phillips LS. Glucose regulated production of human insulin in rat hepatocytes. Gene Ther 2000; 7: 205-14
47. Alam T, Sollinger HW. Glucose-regulated insulin production in hepatocytes. Transplantation 2002; 74: 1781-7
48. Guan J, Behme MT, Zucker P, et al. Glucose turnover and insulin sensitivity in rats with pancreatic islet transplants. Diabetes 1998; 47: 1020-6
49. UK Department of Health. Diabetes national service framework [online]. Available from URL: http://www.doh.gov.uk/nsf/diabetes/index.htm [Accessed 2004 Jan 06]
50. Pickup J, Keen H. Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care 2002; 25: 593-8
51. Pinget M, Jeandidier N. Long term safety and efficacy of intraperitoneal insulin infusion by means of implantable pumps. Horm Metab Res 1998; 30: 475-86
52. Bode BW, Sabbah HT, Gross TM, et al. Diabetes management in the new millennium using insulin pump therapy. Diabetes Metab Res Rev 2002; 18 Suppl. 1: S14-20
53. Udelsman R, Chen H, Loman K, et al. Implanted programmable insulin pumps: one hundred and fifty-three years of surgical experience. Surgery 1997; 122: 1005-11
54. Mason TM, Gupta N, Goh T, et al. Chronic intraperitoneal insulin delivery, as compared with subcutaneous delivery, improves hepatic glucose metabolism in streptozotocin diabetic rats. Metabolism 2000; 49: 1411-6
55. Lassman-Vague V, Guerci B, Hanaire-Broutin H, et al. Use of implantable insulin pumps: the EVADIAC position. Diabetes Metab 1997; 23: 234-50
56. Robert JJ, Chauvet D, Darmaun D, et al. Hepatic glucose production during intraperitoneal and intravenous closed-loop insulin regulation of blood glucose in type 1 (insulin-dependent) diabetic patients. Diabetologia 1993; 36: 1185-90
57. Jeandidier N, Boullu S, Delatte E, et al. High antigenicity of intraperitoneal insulin infusion via implantable devices: preliminary rat studies. Horm Metab Res 2001; 33: 34-8
58. Waxman K, Soliman MH, Nguyen KH. Absorption of insulin in the peritoneal cavity in a diabetic animal model. Artif Organs 1993; 17: 925-8
59. Renard E, Rostane T, Carriere C, et al. Implantable insulin pumps: infections most likely due to seeding from skin flora determine severe outcomes of pump-pocket seromas. Diabetes Metab 2001; 27: 62-5
60. Renard E, Bouteleau S, Jacques-Apostol D, et al. Insulin underdelivery from implanted pumps using peritoneal route: determinant role of insulin pump compatibility. Diabetes Care 1996; 19: 812-7
61. Renard E, Baldet P, Picot MC, et al. Catheter complications associated with implantable systems for peritoneal insulin delivery: an analysis of frequency, predisposing factors, and obstructing materials. Diabetes Care 1995; 18: 300-6
62. Lougheed W, Woulfe-Flanagan H, Clement J, et al. Insulin aggregation in artificial delivery systems. Diabetologia 1980; 19: 1-19
63. Sluzky V, Klibanov AM, Langer R. Mechanism of insulin aggregation and stabilisation in agitated aqueous solutions. Biotechnol Bioeng 1992; 40: 895-903
64. Gin H, Melki V. Clinical evaluation of a newly designed compliant side port catheter for an insulin implantable pump [letter]. Diabetes Care 2001; 24: 175
65. Boivin S, Belicar P, Melki V. Assessment of in vivo stability of a new insulin preparation for implantable insulin pumps: a randomized multicenter prospective trial. EVADIAC Group (Evaluation dans le Diabete du Traitement par Implants Actifs). Diabetes Care 1999; 22: 2089-90
66. Hanaire-Broutin H, Broussolle C, Jeandidier N, et al. Feasibility of intraperitoneal insulin therapy with programmable implantable pumps in IDDM: a multicenter study. The EVADIAC Study Group (Evaluation dans le Diabete du Traitement par Implants Actifs). Diabetes Care 1995; 18: 388-92
67. Jeandidier N, Boullu S, Busch-Brafin MS, et al. Comparison of antigenicity of Hoechst 21PH insulin using either implantable intraperitoneal pump or subcutaneous external pump infusion in type 1 diabetic patients. Diabetes Care 2002; 25: 84-8
68. Mimura A, Kageyama S, Itoh K, et al. Role of growth hormone in the pathogenesis of dawn phenomenon in IDDM. Nippon Naibunpi Gakkai Zasshi 1992; 68: 600-6
69. Heinemann L, Ampudia-Blasco FJ. Glucose clamps with the Biostator: a critical reappraisal. Horm Metab Res 1994; 26: 579-83
70. Gin H, Catargi B, Rigalleau V, et al. Experience with the Biostator for diagnosis and assisted surgery of 21 insulinomas. Eur J Endocrinol 1998; 139: 371-7
71. Meyerhoff C, Mennel FJ, Sternberg F, et al. Current status of the glucose sensor. Endocrinologist 1996; 6: 332-9
72. Selam JL. Management of diabetes with glucose sensors and implantable insulin pumps: from the dream of the 60s to the realities of the 90s. ASAIO J 1997; 43: 137-42
73. Gough DA, Armour JC, Baker DA. Advances and prospects in glucose assay technology. Diabetologia 1997; 40: S102-7
74. Kamati VV, Gao X, Gao S, et al. A glucose-selective fluorescence sensor based on boronic acid-diol recognition. Bioorg Med Chem Lett 2002; 12: 3373-7
75. Tolosa L, Gryczynski I, Eichhorn LR, et al. Glucose sensor for low-cost lifetime-based sensing using a genetically engineered protein. Anal Biochem 1999; 267: 114-20
76. Sosnitza P, Farooqui M, Saleemuddin M, et al. Application of reversible immobilization techniques for biosensors. Anal Chim Acta 1998; 368: 197-203
77. Renard E. Implantable closed-loop glucose-sensing and insulin delivery: the future for insulin pump therapy. Curr Opin Pharmacol 2002; 2: 708-16
78. Gerritsen M, Jansen JA, Kros A, et al. Performance of subcutaneously implanted glucose sensors: a review. J Invest Surg 1998; 11: 163-74
79. Freckmann G, Kalatz B, Pfeiffer B, et al. Recent advances in continuous glucose monitoring. Exp Clin Endocrinol Diabetes 2001; 109: S347-57
80. Kessler L, Passemard R, Oberholzer J, et al. Reduction of blood glucose variability in type 1 diabetic patients treated by pancreatic islet transplantation: interest of continuous glucose monitoring. Diabetes Care 2002; 25: 2256-62
81. Rebrin K, Steil GM, van Antwerp WP, et al. Subcutaneous glucose predicts plasma glucose independent of insulin: implications for continuous monitoring. Am J Physiol 1999; 277: E561-71
82. Monsod TP, Flanagan DE, Rife F, et al. Do sensor glucose levels accurately predict plasma glucose concentrations during hypoglycemia and hyperinsulinemia? Diabetes Care 2002; 25: 889-93
83. Khalil OS. Spectroscopic and clinical aspects of noninvasive glucose measurements. Clin Chem 1999; 45: 165-77
84. Jaremko J, Rorstad O. Advances toward the implantable artificial pancreas for treatment of diabetes. Diabetes Care 1998; 21: 444-50
85. Marquart LA, Arnold M, Small G. Near infra-red spectroscopic measurement of glucose in a protein matrix. Anal Chem 1993; 65: 3271-8
86. Renard E, Shah R, Miller M et al. Sustained safety and accuracy of central IV glucose sensors connected to implanted insulin pumps and short-term closed-loop trials in diabetic patients. 63rd Annual Scientific Sessions of the American Diabetes Association; 2003 Jun 13-17; New Orleans, 155-OR.
87. Sah H, Chien Y, Park K, et al. New generation therapies. In: Hillery A, Lloyd A, Swarbrick J, editors. Drug delivery and targeting for pharmacists and pharmaceutical scientists. London: Taylor & Francis, 2001
88. Kost J, Langer R. Responsive polymeric delivery systems. Adv Drug Deliv Rev 2001; 46: 125-48
89. Groning R, Walz C. Development of experimental insulin pumps with glucose-controlled release. Int J Pharm 1995; 119: 127-31
90. Albin G, Horbett TA, Ratner BD. Glucose sensitive membranes for controlled delivery of insulin: insulin transport studies. J Control Release 1985; 2: 153-64
91. Albin GW, Horbett TA, Miller SR, et al. Theoretical and experimental studies of glucose sensitive membranes. J Control Release 1987; 6: 267-91
92. Albin G, Horbett T, Ratner B. Glucose sensitive membranes for controlled release of insulin. In: Kost J, editor. Pulsed and self regulated drug delivery. Boca Raton (FL): CRC Press, 1990: 159-85
93. Siegel R. pH-sensitive gels: swelling equilibria, kinetics, and applications for drug delivery. In: Kost J, editor. Pulsed and self regulated drug delivery. Boca Raton (FL): CRC Press, 1990: 129-57
94. Ishihara K, Matsui K. Glucose-responsive insulin release from polymer capsule. J Polymer Sci (C) 1986; 24: 413-7
95. Ishihara K, Kobayashi M, Ishimaru N, et al. Glucose-induced permeation control of insulin through a complex membrane consisting of immobilized glucose-oxidase and a poly(amine). Polym J 1984; 16: 625-31
96. Podual K, Doyle FJ, Peppas N. Glucose-sensitivity of glucose oxidase-containing cationic copolymer hydrogels having poly(ethylene glycol) grafts. J Control Release 2000; 67: 9-17
97. Shimada K, Matsuo S, Sadzuka Y, et al. Determination of incorporated amounts of poly(ethylene glycol)-derivatized lipids in liposomes for the physicochemical characterization of stealth liposomes. Int J Pharm 2000; 203: 255-63
98. Lowman AM, Morishita M, Kajita M, et al. Oral delivery of insulin using pH-responsive complexation gels. J Pharm Sci 1999; 88: 933-7
99. Dorski CM, Doyle FJ, Peppas NA. Preparation and characterization of glucose-sensitive P(MAA-g-EG) hydrogels. Polym Mater Sci Eng Proceed 1997; 76: 281-2
100. Iwata H, Amemiya H, Hata Y, et al. Development of novel semipermeable membranes for self-regulated insulin delivery systems. Proceed Intern Symp Control Rel Bioact Mater 1988; 15: 170-1
101. Iwata H, Matsuda T. Preparation and properties of novel environment-sensitive membranes prepared by graft-polymerization onto a porous membrane. J Membr Sci 1988; 38: 185-99
102. Ito Y, Park YS, Imanishi Y. Visualization of critical pH-controlled gating of a porous membrane grafted with polyelectrolyte brushes. J Am Chem Soc 1997; 119: 2739-40
103. Kim C, Im E, Lim S, et al. Development of glucose-triggered pH-sensitive liposomes for a potential insulin delivery. Int J Pharm, 1994; 101: 191-7
104. Chung D-J, Ito Y, Imanishi Y. An insulin-releasing membrane system on the basis of oxidation reaction of glucose. J Control Release 1992; 18: 45-54
105. Ito Y, Imanishi Y. Protein device for glucose-sensitive release of insulin. ACS Symp Ser 1994; 545: 47-54
106. Fischel-Ghodsian F. Enzymatically controlled drug delivery. Proc Natl Acad Sci USA 1988; 85 (7): 2403-6
107. Brown LR, Edelman ER, Fischel-Ghodsian F, et al. Characterization of glucose-mediated insulin release from implantable polymers. J Pharm Sci 1996; 85: 1341-5
108. Kitano S, Kataoka K, Koyama Y, et al. Glucose responsive complex formation between poly(vinyl alcohol) and poly(N-vinyl-2-pyrrolidone) with pendent phenylboronic acid moieties. Makromol Chem Rapid Common 1991; 12: 227-33
109. Kitano S, Koyama Y, Kataoka K, et al. A novel drug delivery system utilising a glucose responsive complex formation between poly(vinyl alcohol) and poly(N-vinyl-2-pyrrolidone) with a pendent phenylboronic acid moiety. J Control Release 1992; 19: 162-70
110. Shiino D, Murata Y, Kubo A, et al. Amine containing phenylboronic acid gel for glucose-responsive insulin release under physiological pH. J Control Release 1995; 37: 269-76
111. Shiino D, Kubo A, Murata Y, et al. Amine effect on phenylboronic acid compiler with glucose under physiological pH in aqueous solution. J Biomater Sci Polym Ed 1996; 7: 697-705
112. Mayes A, Andersson L, Mosbach K. Sugar binding polymers showing high anomeric and epimeric discrimination obtained by noncovalent molecular imprinting. Anal Biochem, 1994; 222: 483-8
113. Weatherman RV, Mortell KH, Chervenak M, et al. Specificity of C-glycoside complexation by mannose-glucose specific lectins. Biochemistry 1996; 35: 3619-24
114. Brownlee M, Cerami A. A glucose controlled insulin delivery system: semisynthetic insulin bound to lectin. Science 1979; 206: 1190-1
115. Brownlee M, Cerami A. Glycosylated insulin complexed to concanavalin A: biochemical basis for a closed-loop insulin delivery system. Diabetes 1983; 32: 499-504
116. Jeong SY, Kim SW. Self regulating insulin delivery systems (I): synthesis and characterisation of glycosylated insulin. J Control Release 1984; 1: 57-66
117. Jeong SY, Kim SW, Holmberg DL, et al. Self-regulating insulin delivery systems (III): in-vivo studies. J Control Release 1985; 2: 143-52
118. Kim S, Jeong S, Sato S, et al. Self-regulating insulin delivery system: a chemical approach. In: Anderson J, Kim S, editors. Recent advances in drug delivery systems. New York: Plenum Press, 1984: 123-36
119. Kim SW, Pai CM, Makino K, et al. Self-regulated glycosylated insulin delivery. In: Anderson J, Kim S, Knutson K, editors. Fourth international symposium on recent advances in drug delivery systems. Amsterdam: Elsevier, 1990: 193-201
120. Kim S, Jacobs H. Self-regulated insulin delivery: artificial pancreas. Drug Dev Ind Pharm 1994; 20: 575-80
121. Pai CM, Bae YH, Mack EJ, et al. Concanavalin A microspheres for a self-regulating insulin delivery system. J Pharm Sci 1992; 81: 532-6
122. Sato S, Jeong SY, McRea JC, et al. Glucose-stimulated insulin delivery systems. Pure Appl Chem 1984; 56 (10): 1323-1328
123. Sato S, Jeong SY, McRae JC, et al. Self-regulating insulin delivery systems (II): in vitro studies. J Control Release 1984; 1: 67-77
124. Seminoff LA, Olsen GB, Kim SW. A self-regulating insulin delivery system (I): characterization of a synthetic glycosylated insulin derivative. Int J Pharm 1989; 54: 241-50
125. Kokufata E, Zhang Y, Tanaka T. Saccharide-sensitive phase transition of a lectin loaded gel. Nature 1991; 351: 302-4
126. Nakamae K, Miyata T, Jikihara A, et al. Formation of poly(glucosyloxyethyl methacrylate): concanavalin A complex and its glucose-sensitivity. J Biomater Sci Polym Ed 1994; 6: 79-90
127. Okahata Y, Nakamura G, Noguchi H. Functional capsule membranes (Pt 29): concanavalin-A-induced permeability control of capsule membranes corked with synthetic glycolipid bilayers or grafted with synthetic glycopolymers. J Chem Soc Perkin 2 Trans 1987: 1317-22
128. Tomioka K, Fukuda H, Taniguchi H. Insulin delivery system based on an affinity chemical valve. J Ferment Bioeng 1994; 77: 442-4
129. Miyata T, Jikihara A, Nakamae K, et al. Preparation of poly(2-glucoyloxyethyl methacrylate) concanavalin A complex hydrogel and its glucose-sensitivity. Macromol Chem Phys 1996; 197: 1135-46
130. Beyer U, Ehwald R, Fleischer L-G. Post-stress thickening of dextran/concanavalin A solutions used as sensitive fluids in a viscosimetric affinity assay for glucose. Biotechnol Prog 1997; 13: 722-6
131. Valuev IL, Chupov VV, Sytov GA, et al. Phase-reversible hydrogels based on acrylamide-N-(2-D-glucose)acrylamide copolymers. Polym Sci Ser B 1997; 39: 156-58
132. Ballerstadt R, Ehwald R. Suitability of aqueous dispersions of dextran and concanavalin A for glucose sensing in different variants of the affinity sensor. Biosens Bioelectron 1994; 9: 557-67
133. Beyer U, Ehwald R. Compensation of temperature and concanavalin A concentratration effects for glucose determination by the viscometric affinity assay. Biotechnol Prog 2000; 16: 1119-23
134. Ehwald R, Ballerstadt R, Dautzenberg H. Viscosimetric affinity assay. Anal Biochem 1996; 234: 1-8
135. Taylor M, De Montfort University. Drug system. Patent application 9200638.6 (drug system I), patent WO 93/13803. US patent 5,830,506, 1998 (divisional 09/124,694 pending). European Patent No. EP0,626,862 B11999 (issued 1992)
136. Taylor MJ, Tanna S, Cockshott S, et al. A novel self regulated delivery system using unmodified solutes in glucose sensitive get membranes. In: Sam A, editor. Proceedings of the Third European Symposium on Controlled Drug Delivery; 1994 Apr 6-8. Noordwijk: Controlled Release Society, 1994: 240-5
137. Taylor MJ, Tanna S. A self regulated delivery system using unmodified solutes in glucose sensitive gel membranes [abstract]. J Pharm Pharmacol 1994; 46: 1051A
138. Tanna S, Taylor MJ. A self regulating delivery system using high molecular weight solutes in glucose sensitive gel membranes [abstract]. J Pharm Pharmacol 1994; 46: 1051B
139. Tang M, Zhang R, Bowyer A, et al. A reversible hydrogel membrane for controlling the delivery of macromolecules. Biotechnol Bioeng 2003; 82: 47-53
140. Obaidat A, Park K. Glucose-dependent release of proteins through glucose-sensitive phase-reversible hydrogel membranes [abstract no. 160]. American Chemical Society 2nd International Symposium on Biorelated Polymers: Advances in Polymeric Drugs and Drug Design; 1996 Aug 25-30; Orlando
141. Obaidat AA, Park K. Characterization of glucose dependent gel-sol phase transition of the polymeric glucose-concanavalin A hydrogel system. Pharm Res 1996; 13: 989-95
142. Kim JJ, Park K. Glucose-binding property of pegylated concanavalin A. Pharm Res 2001; 18: 794-9
143. Kim JJ, Park K. Modulated insulin delivery from glucose-sensitive hydrogel dosage forms. J Control Release 2001; 77: 39-47
144. Taylor MJ, Tanna S, Taylor PM, et al. The delivery of insulin from aqueous and non-aqueous reservoirs governed by a glucose sensitive gel membrane. J Drug Target 1995; 3: 209-16
145. Taylor M, De Montfort University. Drug system II. Patent application 9313484.9, patent WO 95/01186. US patent 5,902,607 1999 (divisional 09/124,445 pending). European Patent Application No. 94,918,945.0; PCT EP0706401 (pending), 1993
146. Tanna S, Taylor M. Characterization of model solute and insulin delivery across covalently modified lectin-polysaccharide gels sensitive to glucose. J Pharm Pharmacol Commun 1998; 4: 117-22
147. Tanna S, Taylor M, Adams G. Insulin delivery governed by covalently modified lectin-glycogen gels sensitive to glucose. J Pharm Pharmacol 1999; 51: 1093-8
148. Kim J, Park K. Immobilization of concanavalin A to glucose containing polymers. Makromol Symp 2001; 172: 95-102
149. Tang M, Zhang R, Bowyer A, et al. A reversible hydrogel membrane for controlling the delivery of macromolecules. Biotechnol Bioeng 2003; 82: 47-53
150. Miyata T, Asami N, Uragami T. A reversibly antigen-responsive hydrogel. Nature 1999; 399: 766-9
151. Tanna S, Sahota T, Clark J, et al. Covalent coupling of concanavalin A to a carbopol 934P and 941P carrier in glucose-sensitive gels for delivery of insulin. J Pharm Pharmacol 2002; 54: 1461-9
152. Tanna S, Sahota T, Clark J, et al. A covalently stabilised glucose responsive gel formulation with a carbopol carrier. J Drug Target 2002; 10: 411-8
153. Tanna S, Taylor MJ, Sahota TS. Viscoelastic properties of a novel glucose-sensitive gel for self-regulated insulin delivery [abstract]. J Pharm Pharmacol 2002; 54: S17
154. Taylor MJ, Clark J, Sahota TS, et al. Self-regulated insulin delivery in-vivo [abstract]. J Pharm Pharmacol 2002; 54: S20
155. Taylor M. Improving insulin therapy. Drug Deliv Syst Sci 2002; 1: 101-5
156. Taylor M, Clark J, Tanna S, et al. Closed loop insulin delivery in vivo. Drug Deliv Syst Sci 2003; 3: 11-7
157. Seong H, Lee HB, Park K. Glucose binding to molecularly imprinted polymers. J Biomater Sci Polym Ed 2002; 13: 637-49
158. Li T, Lee HB, Park K. Comparative stereochemical analysis of glucose-binding proteins for rational design of glucose-specific agents. J Biomater Sci Polym Ed 1998; 9: 327-44